Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Advanced Malignant Solid Neoplasm: early-phase trial registry
27 of 109 indexed Advanced Malignant Solid Neoplasm trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #117 of 28,707 conditions by registered trial count.
109 US clinical trials · 27 currently recruiting · #117 of 28,707 conditions by registered trial count
Advanced Malignant Solid Neoplasm: 109 US clinical trials tracked, 27 recruiting.
Advanced Malignant Solid Neoplasm is the subject of 109 registered US clinical trials on ClinicalTrials.gov, 27 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 99 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 67 of these trials.
Enrollment posture brief
Registry condition advanced-malignant-solid-neoplasm
OPEN 27 | RECR 25% | LATE 1 | EARLY 99 | RANK #117 | SPON 67
Volume-matched condition peers
Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)
Advanced Malignant Solid Neoplasm lists 27 open slots (25% of 109 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Advanced Malignant Solid Neoplasm on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Advanced Malignant Solid Neoplasm is recruiting below its size-band peers.
27 of 109 indexed trials (24.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Advanced Malignant Solid Neoplasm research.
National Cancer Institute (NCI) accounts for 67 of 109 trials (61.5%). 17 distinct sponsors appear on at least one study for this condition label.
-
Most Advanced Malignant Solid Neoplasm trials plan to enrol fewer than 100 people.
Median target enrolment is 45 among the 109 trials that report a genuine target (sentinel values excluded). 86 of those (78.9%) plan for fewer than 100 participants.
-
Advanced Malignant Solid Neoplasm research is mostly interventional.
106 interventional and 3 observational studies make up this index (97.2% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
109 total, page 3 of 3
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02159989
BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers
M.D. Anderson Cancer Center
NCT04021043
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
National Cancer Institute (NCI)
NCT02070549
Ribociclib and Gemcitabine Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors
Mayo Clinic
NCT03237390
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer
University of Washington
NCT02451553
Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
M.D. Anderson Cancer Center
NCT02152943
Cabozantinib S-Malate in Treating Patients With Advanced Solid Tumors and Human Immunodeficiency Virus
National Cancer Institute (NCI)
NCT01822522
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
NCT03526250
SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies
Ronald Levy
NCT03831295
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 44 |
| Phase 2 | 55 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Advanced Malignant Solid Neoplasm records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Advanced Malignant Solid Neoplasm trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Advanced Malignant Solid Neoplasm page
109 registered trials, 27 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 27 Advanced Malignant Solid Neoplasm trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Advanced Malignant Solid Neoplasm trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Advanced Malignant Solid Neoplasm condition card totals 109 registered trials; most-linked intervention Biospecimen Collection; top US site state Pennsylvania. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.